PubMed HealthSearch

PubMed · 1875183

Thyroid hormone. Basis for its hypocholesterolemic effect.

Abstract

The liver is the key organ involved in cholesterol homeostasis. Thyroid hormone binds to nuclear receptors in the liver and thereby acts to alter the expression of several genes coding for proteins involved in cholesterol homeostasis. The expression of apo B-100, the major protein of LDL, is markedly decreased by thyroid hormone while expression of apo A-I, the major protein of HDL, is profoundly increased by thyroid hormone. The thyroid hormone acts to increase hepatic LDL receptor and cholesterol 7 alpha hydroxylase gene expression. The increase in cholesterol 7 alpha hydroxylase, the enzyme which catalyzes the rate-limiting reaction in the degradation of cholesterol to form bile acids, occurs the most rapidly (within one hour) and requires low physiological doses of hormone. Inspection of the 5' flanking region of the cholesterol 7 alpha hydroxylase gene revealed two possible thyroid responsive elements, suggesting that thyroid hormone may exert a primary effect on this gene. The alterations in gene expression produced by thyroid hormone would be expected to result in decreased LDL levels because of decreased apo B-100 synthesis, increased HDL to assist in reverse cholesterol transport from peripheral tissue to the liver, increased removal of LDL from blood by increased hepatic LDL receptors, and increased elimination of cholesterol as neutral sterols and bile acids due to increased cholesterol 7 alpha hydroxylase. These actions would lead to lower serum cholesterol levels.

Explore related subjects

Keep this discovery

Explore connections, maps & timelines

BibTeXRIS

G C Ness. 1991. Thyroid hormone. Basis for its hypocholesterolemic effect.. https://pubmed.ncbi.nlm.nih.gov/1875183/

Cite the original work for its findings. Save a collection to share your selection of sources.

KEEP EXPLORING

Related citations

Membrane fluidity and oxygen diffusion in cholesterol-enriched erythrocyte membrane.

This work studied the effect of cholesteryl hemisuccinate incorporation on membrane fluidity and on the kinetics of oxygen diffusion at different depths in the erythrocyte membrane. Cholesterol concentration in the membrane was expressed as the cholesterol-protein ratio (C/Pt). The membrane fluidity, as assessed by a fluorescence polarization method with diphenyl-hexatriene and 1-(4-trimethylamino)-6-phenylhexa-1,3,5-triene, decreased as the C/Pt ratio increased. Time-resolved fluorescence spectroscopy of pyrene dodecanoic acid (PDA) under an increasing C/Pt ratio in the erythrocyte membrane revealed enhanced oxygen diffusion in the middle of the membrane bilayer (in which PDA was incorporated), which was not the case with pyrene butyric acid (PBA) incorporated in the internal part of the membrane surface. It has generally been accepted that increased membrane fluidity reduces the physical barrier to oxygen permeation. Such conflicting observations on oxygen permeation in the rigidified erythrocyte membrane could be due to variations in oxygen solubility (preferential partitioning) in different polarity microdomains (cholesterol and phospholipid partitions).

Cholesterol

Prevention of coronary heart disease through cholesterol reduction.

Growing evidence suggests that lowering serum cholesterol levels, particularly low-density lipoprotein levels, will reduce the risk for coronary heart disease. The benefit of cholesterol-lowering therapy has been documented by many clinical trials. Two secondary prevention trials, the Scandinavian Simvastatin Survival Study and the Cholesterol and Recurrent Events trial, demonstrated a striking reduction in recurrent coronary heart disease without an increase in noncardiovascular mortality; treatment with simvastatin reduced total mortality by 30 percent. A primary prevention trial, the West of Scotland Coronary Prevention Study, demonstrated similar results in high-risk patients without established coronary heart disease. More recent angiographic trials revealed that cholesterol-lowering therapy will reduce progression of atherosclerosis and, in some cases, will reverse existing lesions. Use of HMG-CoA reductase inhibitors also appears to be beneficial and safe. Evidence supports cholesterol-lowering therapy in high-risk patients, both with and without established atherosclerotic disease.

Cholesterol